Although NRAS mutations occur at a relatively low frequency in CRC, approximately 3%‐7%, they are highly valuable in comprehensive RAS gene testing before epidermal growth factor receptor–targeted therapy [78]. The gene discussed is EGFR; the disease is colorectal carcinoma.